ARTICLE | Company News
Empresa Brasileira de Hemoderivados e Biotecnologia (Hemobras), Baxter sales and marketing update
November 12, 2012 8:00 AM UTC
Brazilian state company Hemobras granted Baxter the exclusive right to become Brazil's provider of recombinant factor VIII ( rFVIII) to treat hemophilia A over the next 20 years. Baxter will receive p...